Innovate UK

StimOxyGen is a biotechnology company focused on developing innovative, pH-responsive nanoparticles. These nanoparticles are designed to generate oxygen in hypoxic (low oxygen) tumors, enhancing the effectiveness of cancer treatments like radiotherapy and chemotherapy. The company's core technology involves a nanoparticle formulation that dissolves in the low pH environment of tumors, transiently producing oxygen and thereby maximizing the therapeutic effects of radiotherapy.

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Esox Biologics provides innovative and sustainable solutions for aquatic veterinary medicine. The company offers a disease prediction platform called eForesee, which uses data-driven predictions unique to individual farms. Regular monitoring of the aquatic environment and livestock health is a key component of their services. Esox Biologics utilizes extensive knowledge of the aquatic microbiome to prevent the spread of infectious diseases among aquatic animals by collecting environmental DNA and employing next-generation sequencing technologies.

New Wave Biotech specializes in downstream process optimization software for alternative protein and synthetic biology products. Utilizing computational modeling and AI, the company conducts virtual experiments on billions of potential processes to provide data-driven recommendations, accelerating R&D and reducing production costs.

New Wave Biotech specializes in downstream process optimization software for alternative protein and synthetic biology products. Utilizing computational modeling and AI, the company conducts virtual experiments on billions of potential processes to provide data-driven recommendations, accelerating R&D and reducing production costs.

Dia Beta Labs is a biotechnology company dedicated to improving the lives of individuals with metabolic diseases. It operates from Ulster, where it has access to advanced facilities and a network of experts. The company's focus is on developing therapeutic agents to address the decline of pancreatic health in patients, with the goal of achieving more sustainable and effective weight loss than current options. Its discovery platform uses industry-standard methodologies and models to identify and advance lead molecules for animal research.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

BindEthics is a business specializing in the production and supply of eco-friendly adhesives. Their primary product is a sustainable, non-toxic glue that is not derived from fossil fuels. This innovative adhesive is designed to replace traditional, petroleum-based adhesives, particularly in the manufacturing of engineered wood products like furniture. By offering a bio-based alternative, BindEthics enables its customers to produce non-toxic, sustainable, and recyclable products, thereby promoting a more environmentally responsible approach to manufacturing.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

Mestag Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and inflammatory diseases through its unique fibroblast technology. The company leverages emerging insights into the role of activated fibroblast populations in disease progression to create therapeutics that disrupt fibroblast-mediated effects on immune cells. By targeting these mechanisms, Mestag aims to enhance treatment options and improve outcomes for patients suffering from rare and life-threatening conditions.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

BoobyBiome operates a microbiome research platform and develops probiotic supplements for infants with compromised microbiomes, including premature babies, to promote gut health and immune development by closely mirroring the beneficial bacteria found in breast milk.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

AgriSound is an agri-tech company that specializes in advanced sound analysis to monitor insect activity, particularly focusing on pollinators. The company has developed a pollination management platform that utilizes sound, environmental, and visual technology sensors to record and analyze insect behavior in near real-time. This innovative approach allows beekeepers, farmers, and researchers to remotely manage beehives and gain insights into hive status and pollination dynamics. By employing predictive algorithms, AgriSound's platform helps identify subtle changes that may impact pollination, enabling users to make informed decisions and take appropriate actions to maintain optimal pollination conditions. Ultimately, AgriSound aims to enhance agricultural operations while promoting biodiversity.

Fuse Diagnostics develops innovative diagnostic products designed to deliver lab-quality information quickly and at a lower cost. Their solutions cater to food and water testing, bioprocessing industries, and cell biology research.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

BSF Enterprise specializes in biotech solutions, focusing on cell-based tissue engineering. Its primary products include cultured meat, lab-grown leather, human corneas, collagen growth, and skin substitutes.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

SökerData is a biotechnology company that specializes in research and data analysis solutions focused on disease-related datasets. The company has developed a data visualization platform designed to analyze biomarkers in clinical outcomes across various demographics. This platform provides researchers with essential features and tools for interpreting large datasets, facilitating early drug discovery. By enabling researchers to better understand the impact of biomarkers on different populations, SökerData supports informed decision-making and enhances the comprehension of disease outcomes in diverse demographic groups.

Aelius Biotech specializes in developing models of the mucosal surfaces within the human body. Currently, they focus on simulating the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Concr is a mission-driven techbio company that uses established methods from astrophysics to predict patient outcomes and treatment response to cancer therapies. The approach enables iterative learning from fragmented data across the drug development and clinical journey, producing accurate multi-modal tumor models without relying on large, homogeneous datasets. Its cloud-native platform FarrSight supports computational simulation of clinical trials, prediction of therapeutic response and biomarkers, and standard bioinformatics analyses. Headquartered in London with a wholly owned subsidiary in Brisbane, Concr provides a cloud-based system that identifies optimal treatments for individuals, reduces resistance, and offers patient-specific progression insights and evidence-based treatment plans to guide proactive therapy.

PulmoBioMed is a company focused on providing innovative solutions for clinicians and researchers through non-invasive sampling of fluids. The firm has developed a passive fluid aerosol sampler designed to capture exhaled breath condensate and aerosol samples. This product effectively segregates exhaled and environmental particles by size, addressing critical challenges such as sample contamination and loss. PulmoBioMed's technology aims to generate highly reproducible data with precise digital molecular analysis, facilitating the study of biological agents and supporting metabolomic profiling. Through its advancements, the company seeks to enhance research capabilities and improve patient outcomes in the field of respiratory health.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

Cellcraft is a Cambridge-based B2B cultivated meat company building a scalable manufacturing platform for cultured meat. It combines AI-driven software, advanced technologies, and targeted raw materials to help food producers locally manufacture cultivated meats more sustainably. The company applies tissue engineering and biomimetic systems to harvest animal cells in controlled environments, enabling commercial-scale production of cultured meats tailored to local tastes and specifications. By enabling local production, Cellcraft addresses global food security and sustainability challenges and aims to democratize access to sustainable protein.

Clean Food Group develops sustainable food ingredients and fats and oils alternatives, ranging from liquid oils such as soybean to hard fats like palm oil, cocoa butter, and milk fat, aimed at reducing environmental impact while preserving taste and performance. It also builds a cellular agriculture system to commercialize palm oil production by fermentation using proprietary non-GM yeast, providing a sustainable, local, and circular alternative to traditional palm oil that does not contribute to deforestation.

CellRev is a biotechnology company specializing in process intensification for cell manufacturing. Its proprietary technology enables the transition from batch to continuous processing of adherent cells, increasing yields while reducing operating costs and capital expenditure.

SynaptixBio is a biotechnology company focused on developing innovative therapies for severe leukodystrophies, particularly targeting TUBB4a Leukodystrophy. By addressing the root causes of these conditions, SynaptixBio aims to provide potential curative treatments that could significantly disrupt existing treatment practices. The company is dedicated to translating groundbreaking research into transformative therapeutic options, specifically by altering the expression of a mutated gene responsible for the disease. Through its efforts, SynaptixBio seeks to deliver lifesaving solutions to those affected by this acute subset of leukodystrophies.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

PES Technologies specializes in innovative agricultural technology, specifically focusing on soil health analysis. The company has developed a microbe sensor that monitors the biological properties of soil by analyzing microbe health. This technology provides valuable insights into the long-term changes in soil quality, enabling farmers and agronomists to make informed soil management decisions swiftly. By offering a tool to assess soil conditions effectively, PES Technologies contributes to enhancing farming practices and promoting sustainable agriculture.

PES Technologies specializes in innovative agricultural technology, specifically focusing on soil health analysis. The company has developed a microbe sensor that monitors the biological properties of soil by analyzing microbe health. This technology provides valuable insights into the long-term changes in soil quality, enabling farmers and agronomists to make informed soil management decisions swiftly. By offering a tool to assess soil conditions effectively, PES Technologies contributes to enhancing farming practices and promoting sustainable agriculture.

Laverock Therapeutics develops a gene silencing platform for creating programmable, allogeneic cell therapies.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

The Good Pulse Company develops functional proteins and ingredients derived from pulses for use in plant-based foods and supplements, including plant-based cheeses and meats. It concentrates on maximizing the functionality and nutritional value of components extracted from pulse seeds such as peas and soy, and pursues the production of functional meat proteins through precision fermentation to offer sustainable, ethical food options without compromising taste or experience.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

Carbogenics is a UK-based company that develops and produces sustainable agricultural and waste-to-resource technologies. It focuses on turning disposable coffee cups and other non-recyclable paper waste into value-added products, including carbon-rich materials that stimulate biogas production and improve plant growth, and it offers CreChar as a carbon additive. The company provides plant fertilizer products and consultancy and analytical services for anaerobic digestion facilities, supporting operators in wastewater and biogas applications. Its low-carbon technology converts difficult-to-recycle organic waste into carbon adsorbents used to boost digestion performance and agricultural yields. Founded in 2016 and based in Edinburgh, Carbogenics aims to create circular economy solutions by transforming waste streams into fertilizers, soil amendments, and bio-additives for farming and digestion processes.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

TherageniX specializes in gene therapy for tissue regeneration, focusing on orthopedic applications. The company's patented technology uses a non-viral delivery system to introduce specific genes, such as VEGF and BMP, into autologous bone marrow cells, enhancing their regenerative capacity. This process aids in tissue repair and regeneration, improving functional outcomes and reducing donor site trauma for patients with diseases, injuries, or age-related tissue damage.

Intellegens is a company that specializes in applying machine learning to enhance innovation across various industries, including materials, chemicals, and manufacturing. Its flagship product, Alchemite™, was initially developed at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional machine learning methods often struggle. This platform allows scientists, engineers, and analysts to optimize formulations, products, and processes while significantly reducing the number of experiments required, often by up to 90%. Alchemite™ features a user-friendly web interface and powerful graphical analysis tools, and it can be seamlessly integrated into existing data science workflows. The technology has been successfully applied in multiple fields, including drug discovery, materials development, and additive manufacturing, thereby enabling clients to extract greater value from their data and accelerate their development timelines.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Plasticell is a biotechnology company focused on developing innovative therapeutic solutions through advanced cell culture and drug discovery platforms. By investigating the biochemical mechanisms that govern stem cell behavior, Plasticell aims to create regenerative small molecule drugs that support tissue development and repair. The company offers comprehensive support for researchers in cell biology by enabling the testing of numerous cell culture variables, thereby optimizing laboratory protocols for various outcomes. This approach facilitates the differentiation of cells and enhances processes such as gene transduction and protein production, ultimately contributing to the advancement of novel therapies in regenerative medicine.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Metalchemy is a nanotechnology company focused on green nanomaterials, bio-nanotechnology, and bioplastics. It develops products derived from green nanomaterials and converts waste into nanomaterials, enabling industries to access eco-friendly nanotechnology to reduce food waste and address the climate crisis, with the goal of a healthier and more sustainable future.

NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn is a biotechnology company specializing in the development of advanced wound care solutions. Its flagship product, Heals device, employs contactless technology to revolutionize the treatment of chronic and complex wounds.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

SMi Systems is a biomedical research company that develops single-molecule discovery and diagnostic tools. Its automated, high-throughput platform uses super-resolution microscopy coupled with deep learning for multi-omic detection, enabling drug developers to observe molecular interactions across various diseases.

PfBIO is a biotechnology company that discovers and develops natural, bacteria-based products to enhance plant health and protect crops from diseases, providing sustainable alternatives to synthetic agrochemicals. The company's innovative platform involves sourcing bacteria from the environment and selecting those with the ability to combat plant pathogens, improve crop yields, and enrich soil quality.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Autolomous develops pragmatic software solutions for cell and gene therapy manufacturers. Its platform, autoloMATE®, offers end-to-end solutions including resource scheduling, electronic batch records management, insights reporting, review, and release activities. The platform aligns with US FDA, EU EMA & UK MHRA guidance and is certified ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management).

Orthonika Limited, established in London in 2014, specializes in the manufacture of MenisciKnit, an innovative anatomical meniscus replacement designed to address the high unmet need for effective treatment of meniscus injuries. Its unique fiber-reinforced structure aims to restore full joint biomechanics and reduce the risk of osteoarthritis.

Hexis Lab is a biotechnology company specializing in the research and development of innovative skincare products tailored for diverse skin types. The company focuses on creating ethically targeted solutions aimed at protecting and repairing sun-damaged skin while enhancing overall well-being. Utilizing a discovery platform that incorporates big data cloud computing and in-silico computer modeling, Hexis Lab screens an extensive database of naturally derived plant compounds for their efficacy against specific cellular targets. By leveraging proprietary AI techniques, the company accelerates product research, identifies novel ingredients, and formulates effective products for the beauty, skincare, personal care, nutraceuticals, and pharmaceutical sectors.

ScubaTx is a company focused on developing an advanced organ preservation system that utilizes the Persufflation method, a well-established technique aimed at enhancing organ transportation. By leveraging innovative software design, ScubaTx aims to provide significant cost savings for healthcare providers, thereby facilitating an expanded supply of viable organs for transplantation. The company’s technology is designed to protect and improve the condition of grafts during the preservation process, ultimately empowering clinicians worldwide to increase the availability of life-saving organs.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Flybox® is an Insect Waste Management (IWM) company delivering innovative insect bioconversion technology and expert support to revolutionise waste management. Flybox® provides tailored IWM solutions for established waste and food businesses, alongside a streamlined breeding and monetisation service that simplifies startup and scaling for new operators. Its modular IWM systems integrate seamlessly with existing waste infrastructure, allowing businesses to transform organic waste streams and byproducts into valuable proteins and fertilisers. With patented technology and a steadfast commitment to circular economy principles, Flybox® is advancing global efforts to reduce landfill dependency, minimise reliance on deforestation-linked soy, and enhance food security. Headquartered in the UK and active internationally, Flybox® is a leader in sustainable waste solutions, driving positive change across agriculture, waste management, and environmental resilience.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

QV Bioelectronics develops an innovative electric field therapy implant, GRACE, designed to extend the lives of brain tumor patients while maintaining their quality of life. This first-of-its-kind device targets glioblastoma, a cancer with poor outcomes, by slowing tumor growth and sparing healthy tissue.

Calla Lily Clinical Care is a women's health company focused on developing innovative drug delivery systems. Their proprietary platform, Callavid®, enables intravaginal drug delivery for various indications, including fertility and pregnancy support, prevention of recurrent bacterial vaginosis, hormone replacement therapy for menopause, and biomarker-based diagnostic tests.

GenoMe Diagnostics is a biotechnology company focused on developing innovative blood tests for early cancer detection. Its flagship product, OvaME, aims to improve the current standard of CA125 blood tests.

DeepMirror develops AI-driven drug design software that combines human expertise with artificial intelligence. Its platform aims to help chemists focus on the most promising drug candidates by simplifying complex data analysis workflows, enabling more efficient drug molecule discovery and development.

Elaniti is an agricultural data company that combines machine learning with DNA sequencing to reveal soil microbiome insights for farmers and agronomists. Its platform provides outcome-based predictive analytics that link soil biology to crop health metrics such as yield, disease incidence, and nutrient content, enabling precise decisions and more efficient input use. By decoding the soil microbiome and applying proprietary models, the company aims to improve soil health, increase productivity, and support sustainable farming practices. The approach emphasizes data-driven decision making and aims to enable a de-risked transition toward Net-Zero agriculture by validating the value of soil's biological makeup for growers.

Kelpi is a sustainable biotech startup and material innovation company that uses seaweed to bio-refine a biodegradable bioplastic coating for paper and card packaging. The coating provides a renewable alternative to fossil-fuel plastics used in packaging for food, beverages, cosmetics and personal care, and is designed to be recyclable, biodegradable and home-compostable in suitable environments. By enabling a thin seaweed-based biomaterial to coat paper and card, Kelpi aims to eliminate single-use plastics while delivering marine-safe packaging.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

Multus is a London-based company established in 2019 that specializes in providing tailored growth media solutions for the cultivated meat industry. By utilizing a machine learning-based approach, Multus develops completely animal-free growth media designed specifically for the efficient growth of animal cells. This innovative technology enables cultivated meat companies to scale their production affordably and sustainably, allowing them to focus on creating delicious and environmentally friendly meat alternatives. Additionally, Multus optimizes a variety of growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the reliance on traditional animal serum-based media. Through its efforts, Multus aims to address the diverse needs of various animal cell types and tissues, facilitating the growth of the cultivated meat sector while significantly reducing the environmental and economic impacts associated with conventional meat production.

Concert Bio is a technology company that assists businesses in enhancing their microbial communities' productivity through its proprietary full-stack platform. This platform integrates monitoring, analytics, and intervention strategies to manipulate microbiomes, empowering clients to optimize these communities for improved performance.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

Biome Bioplastics is a manufacturer specializing in the production of biodegradable and compostable bioplastics aimed at replacing conventional oil-based polymers. The company offers a diverse range of products, including high-temperature materials, non-woven fibers, flexible films, and various coating and lamination solutions. By focusing on environmentally sustainable options, Biome Bioplastics addresses the growing demand for materials that perform well both during use and at the end of their life cycle. The company employs multiple processing techniques such as injection molding, sheet extrusion, vacuum forming, and blown film to create innovative bioplastic solutions that allow clients to develop cost-effective, eco-friendly products.

Enhanced Fertility is a digital health company that uses data, artificial intelligence, and remote diagnostics to improve fertility care. It aims to increase access to fertility treatment for the 1 in 6 couples globally facing infertility, with less than 2% currently able to access needed care. The company's platform helps fertility clinics make data-driven clinical decisions, from diagnosis to treatment, to enhance live birth rates. It streamlines the patient pathway, reducing the time to treatment from three years to just 30 days through at-home testing and AI-enabled care.

Vann is a platform for people affected by cancer aiming to help millions of people globally and revolutionize cancer research and care. Vann has been backed by the Oxford University Innovation, Innovate UK, OxLEP European Regional Development Fund, and UK angel investors and is based in the UK.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Adamo Foods is a UK-based company developing plant-based whole-cut meats using proprietary fermentation technology combined with mycelium.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.